AHFS February 2023 Update

This update contains 7 new monographs, 18 revised monographs and 2 new MedWatch alerts.

New monographs: Antihemophilic Factor (recombinant), PEGylated; Cysteamine; Olutasidenib; Teclistamab; Teplizumab-mzwv; Tirzepatide; Varenicline.

Revised monographs: Alirocumab; Antihemophilic Factor (recombinant), PEGylated-aucl; Avacopan; Baricitinib; Bempedoic Acid; Elexacaftor, Tezacaftor, and Ivacaftor; Ibrexafungerp; Lonafarnib; Mobocertinib; Molnupiravir; Ocrelizumab; Palivizumab; Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Pimavanserin; Pirfenidone; Teriflunomide; Tixagevimab and Cilgavimab; Voclosporin.

New MedWatch alerts on the following monographs: Bebtelovimab; Denosumab.